Dr. Michael G. Ison is a Professor at the Northwestern University Feinberg School of Medicine; and Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service, Comprehensive Transplant Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois. He received his medical degree from University of South Florida College of Medicine, Tampa, Florida. He completed a residency in internal medicine at Oregon Health Sciences University, Portland, Oregon, and a fellowship in infectious diseases at the University of Virginia, Charlottesville.
During fellowship, Dr. Ison’s research focused on the immunopathogenesis of influenza and its treatment in immunosuppressed and hospitalized patients. He developed an immunocompromised mouse model of influenza to study the development of antiviral resistance. In addition, he conducted studies of the pharmacokinetics and outcomes of treatment with oseltamivir, zanamivir, and rimantadine in hospitalized patients.
Dr. Ison has continued to be a leader in the respiratory virus research arena. He has been first author of 3 prospective interventional studies of hospitalized patients as well as a lead investigator of studies to determine how to prevent and treat influenza in immunocompromised patients. He has recently provided advice to the President’s H1N1 Subcommittee, the National Institutes of Health, and the Biomedical Advanced Research and Development Authority on issues related to influenza in hospitalized and immunocompromised patients. He was a key opinion leader in the development of peramivir, in addition to several other anti-influenza antiviral agents currently under development. He was involved in the National Institute of Allergy and Infectious Diseases Influenza Research Collaboration, in addition to serving as protocol co-chair of IRC 004. He is also a member of the Infectious Diseases Society of America/Centers for Disease Control and Prevention and the World Health Organization influenza treatment guideline revision committees.